Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Fucosylated α1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer.

Yokobori T, Yazawa S, Asao T, Nakazawa N, Mogi A, Sano R, Kuwano H, Kaira K, Shirabe K.

Sci Rep. 2019 Oct 10;9(1):14503. doi: 10.1038/s41598-019-51021-2.

2.

High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors.

Nakazawa N, Yokobori T, Kaira K, Turtoi A, Baatar S, Gombodorj N, Handa T, Tsukagoshi M, Ubukata Y, Kimura A, Kogure N, Ogata K, Maeno T, Sohda M, Yajima T, Shimizu K, Mogi A, Kuwano H, Saeki H, Shirabe K.

Ann Surg Oncol. 2019 Sep 30. doi: 10.1245/s10434-019-07878-8. [Epub ahead of print]

PMID:
31571056
3.

Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report.

Kosaka T, Yajima T, Yamaki E, Nakazawa S, Tomizawa K, Onozato R, Yamazaki A, Hirato J, Yatabe Y, Shimizu K, Mogi A, Shirabe K.

Mol Clin Oncol. 2019 Sep;11(3):309-312. doi: 10.3892/mco.2019.1892. Epub 2019 Jul 3.

4.

Will minimally invasive sleeve resection become the future trend for treatment of advanced lung cancer?

Kosaka T, Shimizu K, Nakazawa S, Obayashi K, Ohtaki Y, Kawatani N, Ibe T, Yajima T, Mogi A, Shirabe K.

J Thorac Dis. 2019 Apr;11(4):1085-1087. doi: 10.21037/jtd.2019.02.95. No abstract available.

5.

Severe Hemorrhagic Cystitis Caused by Cyclophosphamide and Capecitabine Therapy in Breast Cancer Patients: Two Case Reports and Literature Review.

Tanaka T, Nakashima Y, Sasaki H, Masaki M, Mogi A, Tamura K, Takamatsu Y.

Case Rep Oncol. 2019 Jan 21;12(1):69-75. doi: 10.1159/000496331. eCollection 2019 Jan-Apr.

6.

Pulmonary Artery Compression Facilitates Intersegmental Border Visualization.

Yajima T, Shimizu K, Mogi A, Ibe T, Ohtaki Y, Obayashi K, Nakazawa S, Kawatani N, Shirabe K.

Ann Thorac Surg. 2019 Aug;108(2):e141-e143. doi: 10.1016/j.athoracsur.2019.02.067. Epub 2019 Apr 2.

PMID:
30951697
7.

Medial-basal segment (S7)-sparing right basal segmentectomy.

Yajima T, Shimizu K, Mogi A, Kosaka T, Nakazawa S, Shirabe K.

Gen Thorac Cardiovasc Surg. 2019 Apr 1. doi: 10.1007/s11748-019-01116-4. [Epub ahead of print]

PMID:
30937818
8.

Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma.

Iijima M, Yokobori T, Mogi A, Shimizu K, Yajima T, Kosaka T, Ohtaki Y, Obayashi K, Nakazawa S, Gombodorj N, Tsukagoshi M, Shirabe K, Kuwano H.

Ann Surg Oncol. 2019 Jun;26(6):1744-1750. doi: 10.1245/s10434-019-07268-0. Epub 2019 Mar 28.

PMID:
30924018
9.

Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors.

Shimizu K, Goto Y, Kawabata-Iwakawa R, Ohtaki Y, Nakazawa S, Yokobori T, Obayashi K, Kawatani N, Yajima T, Kaira K, Mogi A, Hirato J, Nishiyama M, Shirabe K.

Ann Thorac Surg. 2019 Jul;108(1):235-243. doi: 10.1016/j.athoracsur.2019.02.040. Epub 2019 Mar 22.

PMID:
30910656
10.

Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas.

Ohtaki Y, Shimizu K, Kawabata-Iwakawa R, Gombodorj N, Altan B, Rokudai S, Yamane A, Kaira K, Yokobori T, Nagashima T, Obayashi K, Nakazawa S, Iijima M, Kosaka T, Yajima T, Mogi A, Kuwano H, Shirabe K, Nishiyama M.

Oncotarget. 2019 Feb 12;10(13):1306-1319. doi: 10.18632/oncotarget.26657. eCollection 2019 Feb 12.

11.

Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.

Kasahara N, Sunaga N, Tsukagoshi Y, Miura Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, Asao T, Hisada T.

Anticancer Res. 2019 Mar;39(3):1455-1461. doi: 10.21873/anticanres.13262.

PMID:
30842182
12.

[Wedge Resection as an Alternative Procedure for Primary Pulmonary Carcinoma in Poor-risk Patients].

Kamiyoshihara M, Igai H, Yoshikawa R, Ohsawa F, Yazawa T, Shimizu K, Mogi A, Shirabe K.

Kyobu Geka. 2019 Jan;72(1):4-10. Japanese.

PMID:
30765622
13.

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin.

Matsuoka T, Yoshida Y, Aisu N, Yamada T, Mogi A, Komono A, Sakamoto R, Kojima D, Yoshimatsu G, Kiyomi F, Kodama S, Hasegawa S.

Sci Rep. 2019 Feb 12;9(1):1819. doi: 10.1038/s41598-018-37966-w.

14.

Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response.

Yajima T, Hoshino K, Muranushi R, Mogi A, Onozato R, Yamaki E, Kosaka T, Tanaka S, Shirabe K, Yoshikai Y, Kuwano H.

Mol Immunol. 2019 Mar;107:97-105. doi: 10.1016/j.molimm.2019.01.014. Epub 2019 Jan 30.

PMID:
30711908
15.

Is salvage surgery for patients with lung cancer after carbon ion radiotherapy easy or difficult?

Ohtaki Y, Shimizu K, Saitoh JI, Kamiyoshihara M, Mogi A, Nakazawa S, Ohno T, Shirabe K.

Interact Cardiovasc Thorac Surg. 2019 Jun 1;28(6):953-956. doi: 10.1093/icvts/ivy350.

PMID:
30649311
16.

Autoimmune Hepatitis with Concomitant Idiopathic Thrombocytopenic Purpura Diagnosed by Transjugular Liver Biopsy.

Fukuda H, Takata K, Kitaguchi T, Yamauchi R, Kunimoto H, Tanaka T, Yokoyama K, Morihara D, Takeyama Y, Shakado S, Mogi A, Kora S, Koga K, Takeshita M, Yoshimitsu K, Sakisaka S.

Case Reports Hepatol. 2018 Dec 9;2018:5305691. doi: 10.1155/2018/5305691. eCollection 2018.

17.

A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?

Obayashi K, Shimizu K, Nakazawa S, Ohtaki Y, Kawatani N, Takashi I, Yajima T, Mogi A, Shirabe K.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4113-S4116. doi: 10.21037/jtd.2018.10.53. No abstract available.

18.

Prognostic Impact of β2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma.

Kaira K, Kamiyoshihara M, Kawashima O, Endoh H, Imaizumi K, Sugano M, Tanaka S, Fujita A, Kogure Y, Shimizu A, Oyama T, Asao T, Shimizu K, Mogi A.

Anticancer Res. 2019 Jan;39(1):395-403. doi: 10.21873/anticanres.13125.

PMID:
30591486
19.

Minimally Invasive Open-Window Thoracostomy Using Wound Edge Protectors.

Shimizu K, Ohtaki Y, Nakazawa S, Obayashi K, Nagashima T, Yajima T, Mogi A, Shirabe K.

Ann Thorac Surg. 2019 May;107(5):e371-e373. doi: 10.1016/j.athoracsur.2018.10.064. Epub 2018 Dec 5.

PMID:
30529214
20.

The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer.

Obayashi K, Shimizu K, Nakazawa S, Nagashima T, Yajima T, Kosaka T, Atsumi J, Kawatani N, Yazawa T, Kaira K, Mogi A, Kuwano H.

J Thorac Dis. 2018 Sep;10(9):5428-5434. doi: 10.21037/jtd.2018.08.118.

21.

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.

Ohtaki Y, Kaira K, Atsumi J, Nagashima T, Kawashima O, Ibe T, Kamiyoshihara M, Onozato R, Fujita A, Yazawa T, Sugano M, Iijima M, Nakazawa S, Obayashi K, Kosaka T, Yajima T, Kuwano H, Shirabe K, Mogi A, Shimizu K.

Am J Transl Res. 2018 Oct 15;10(10):3243-3253. eCollection 2018.

22.

Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma.

Kaira K, Kawashima O, Endoh H, Imaizumi K, Goto Y, Kamiyoshihara M, Sugano M, Yamamoto R, Osaki T, Tanaka S, Fujita A, Imai H, Kogure Y, Seki Y, Shimizu K, Mogi A, Shitara Y, Oyama T, Kanai Y, Asao T.

Hum Pathol. 2019 Feb;84:142-149. doi: 10.1016/j.humpath.2018.09.020. Epub 2018 Oct 6.

PMID:
30300664
23.

2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.

Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, Ohtaki Y, Higuchi T, Oyama T, Asao T, Mogi A.

Eur J Cancer. 2018 Sep;101:181-190. doi: 10.1016/j.ejca.2018.06.022. Epub 2018 Aug 1.

PMID:
30077123
24.

Thoracoscopic right middle lobe segmentectomy.

Yajima T, Shimizu K, Mogi A, Kosaka T, Nakazawa S, Shirabe K.

Gen Thorac Cardiovasc Surg. 2019 Mar;67(3):344-347. doi: 10.1007/s11748-018-0964-4. Epub 2018 Jun 25.

PMID:
29943168
25.

[Multidisciplinary Approach to Recurrence after Resection of Primary Lung Cancer].

Kamiyoshihara M, Igai H, Ibe T, Ohsawa F, Yoshikawa R, Shimizu K, Mogi A, Shirabe K, Kuwano H.

Kyobu Geka. 2018 Apr;71(4):302-310. Japanese.

PMID:
29755104
26.

Ectopic thymoma in the paratracheal region of the middle mediastinum: a rare case report and literature review.

Yajima T, Mogi A, Shimizu K, Kosaka T, Nagashima T, Ohtaki Y, Obayashi K, Nakazawa S, Iijima M, Yoshida Y, Hirato J, Kuwano H.

BMC Res Notes. 2018 Apr 25;11(1):256. doi: 10.1186/s13104-018-3359-9. Review.

27.

Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.

Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, Sunaga N, Ohtaki Y, Yajima T, Kosaka T, Oyama T, Yokobori T, Asao T, Nishiyama M, Tsushima Y, Kuwano H, Shimizu K, Mogi A.

Lung Cancer. 2018 May;119:71-77. doi: 10.1016/j.lungcan.2018.03.001. Epub 2018 Mar 16.

PMID:
29656756
28.

Low diffusing capacity, emphysema, or pulmonary fibrosis: who is truly pulling the lung cancer strings?

Nakazawa S, Shimizu K, Mogi A, Kuwano H.

J Thorac Dis. 2018 Feb;10(2):600-602. doi: 10.21037/jtd.2017.12.145. No abstract available.

29.

Entrainment of the Circadian Clock in Neural Stem Cells by Epidermal Growth Factor is Closely Associated with ERK1/2-mediated Induction of Multiple Clock-related Genes.

Mogi A, Yomoda R, Kimura S, Tsushima C, Takouda J, Sawauchi M, Maekawa T, Ohta H, Nishino S, Kurita M, Mano N, Osumi N, Moriya T.

Neuroscience. 2018 May 21;379:45-66. doi: 10.1016/j.neuroscience.2018.02.045. Epub 2018 Mar 6.

PMID:
29518531
30.

High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.

Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.

Oncol Lett. 2018 Mar;15(3):3061-3067. doi: 10.3892/ol.2017.7671. Epub 2017 Dec 20.

31.

VATS segmentectomy: past, present, and future.

Nakazawa S, Shimizu K, Mogi A, Kuwano H.

Gen Thorac Cardiovasc Surg. 2018 Feb;66(2):81-90. doi: 10.1007/s11748-017-0878-6. Epub 2017 Dec 18. Review.

PMID:
29255967
32.

Histamine N-methyltransferase regulates aggression and the sleep-wake cycle.

Naganuma F, Nakamura T, Yoshikawa T, Iida T, Miura Y, Kárpáti A, Matsuzawa T, Yanai A, Mogi A, Mochizuki T, Okamura N, Yanai K.

Sci Rep. 2017 Nov 21;7(1):15899. doi: 10.1038/s41598-017-16019-8.

33.

3D-CT anatomy for VATS segmentectomy.

Shimizu K, Nakazawa S, Nagashima T, Kuwano H, Mogi A.

J Vis Surg. 2017 Jul 1;3:88. doi: 10.21037/jovs.2017.05.10. eCollection 2017. Review.

34.

Thoracoscopic Subsuperior Segment Segmentectomy.

Shimizu K, Mogi A, Yajima T, Nagashima T, Ohtaki Y, Obayashi K, Nakazawa S, Kosaka T, Kuwano H.

Ann Thorac Surg. 2017 Nov;104(5):e407-e410. doi: 10.1016/j.athoracsur.2017.07.007.

PMID:
29054241
35.

Thoracoscopic Medial-Basal Segment Segmentectomy.

Shimizu K, Nagashima T, Yajima T, Ohtaki Y, Obayashi K, Nakazawa S, Kosaka T, Mogi A, Kuwano H.

Ann Thorac Surg. 2017 Nov;104(5):e403-e406. doi: 10.1016/j.athoracsur.2017.07.006.

PMID:
29054240
36.

Segmentectomy of the left superior segment (S6) 4 years after segmentectomy of the left dorsobasal segment (S10).

Shimizu K, Nakazawa S, Mogi A, Kuwano H.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1302-1304. doi: 10.1016/j.jtcvs.2017.08.119. Epub 2017 Sep 13. No abstract available.

PMID:
28986040
37.

Clinical and Radiological Discrimination of Solitary Pulmonary Lesions in Colorectal Cancer Patients.

Ohtaki Y, Shimizu K, Nagashima T, Nakazawa S, Obayashi K, Azuma Y, Iijima M, Kosaka T, Yajima T, Ogawa H, Tsutsumi S, Arai M, Mogi A, Kuwano H.

World J Surg. 2018 Apr;42(4):1161-1170. doi: 10.1007/s00268-017-4243-9.

PMID:
28983707
38.

High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.

Bao P, Yokobori T, Altan B, Iijima M, Azuma Y, Onozato R, Yajima T, Watanabe A, Mogi A, Shimizu K, Nagashima T, Ohtaki Y, Obayashi K, Nakazawa S, Bai T, Kawabata-Iwakawa R, Asao T, Kaira K, Nishiyama M, Kuwano H.

Ann Surg Oncol. 2017 Dec;24(13):4017-4024. doi: 10.1245/s10434-017-6083-0. Epub 2017 Sep 20.

PMID:
28933054
39.

Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S.

Clin Exp Nephrol. 2018 Feb;22(1):210-244. doi: 10.1007/s10157-017-1448-z. Review. No abstract available.

40.

Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. doi: 10.1007/s00259-017-3806-1. Epub 2017 Aug 21.

PMID:
28828507
41.

Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.

Tanaka T, Ueno M, Nakashima Y, Chinen S, Sato E, Masaki M, Mogi A, Sasaki H, Tamura K, Takamatsu Y.

Thorac Cancer. 2017 Sep;8(5):523-529. doi: 10.1111/1759-7714.12482. Epub 2017 Jul 25.

42.

Difference in Neutropenia due to Administration Schedule of TAS-102.

Yoshida Y, Aisu N, Mogi A, Komono A, Sakamoto R, Kojima D, Mera T, Hasegawa S.

Case Rep Oncol. 2017 Mar 2;10(1):226-229. doi: 10.1159/000460242. eCollection 2017 Jan-Apr.

43.

JNJ10181457, a histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice.

Iida T, Yoshikawa T, Kárpáti A, Matsuzawa T, Kitano H, Mogi A, Harada R, Naganuma F, Nakamura T, Yanai K.

Biochem Biophys Res Commun. 2017 Jul 1;488(3):534-540. doi: 10.1016/j.bbrc.2017.05.081. Epub 2017 May 16.

PMID:
28526411
44.

Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma.

Shimizu K, Ohtaki Y, Altan B, Yokobori T, Nagashima T, Arai M, Mogi A, Kuwano H.

J Thorac Cardiovasc Surg. 2017 Oct;154(4):1406-1417.e3. doi: 10.1016/j.jtcvs.2017.03.125. Epub 2017 Apr 5.

45.

Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important.

Sasaki H, Tamura K, Naito Y, Ogata K, Mogi A, Tanaka T, Ikari Y, Masaki M, Nakashima Y, Takamatsu Y.

Int J Clin Oncol. 2017 Aug;22(4):793-800. doi: 10.1007/s10147-017-1117-y. Epub 2017 Apr 6.

46.

Analysis of variation in bronchovascular pattern of the right middle and lower lobes of the lung using three-dimensional CT angiography and bronchography.

Nagashima T, Shimizu K, Ohtaki Y, Obayashi K, Nakazawa S, Mogi A, Kuwano H.

Gen Thorac Cardiovasc Surg. 2017 Jun;65(6):343-349. doi: 10.1007/s11748-017-0754-4. Epub 2017 Feb 14.

47.

Characterization of murine polyspecific monoamine transporters.

Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Kárpáti A, Matsuzawa T, Mogi A, Harada R, Yanai K.

FEBS Open Bio. 2017 Jan 9;7(2):237-248. doi: 10.1002/2211-5463.12183. eCollection 2017 Feb.

48.

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.

Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.

Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6.

49.

Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer.

Yazawa T, Kaira K, Shimizu K, Shimizu A, Mori K, Nagashima T, Ohtaki Y, Oyama T, Mogi A, Kuwano H.

Am J Transl Res. 2016 Nov 15;8(11):5059-5070. eCollection 2016.

50.

Histology is a Prognostic Indicator After Pulmonary Metastasectomy from Renal Cell Carcinoma.

Ohtaki Y, Shimizu K, Aokage K, Nakao M, Yoshida J, Kamiyoshihara M, Sugano M, Takahashi Y, Nakazawa S, Nagashima T, Obayashi K, Hishida T, Tsuboi M, Mori S, Mun M, Okumura S, Igai H, Matsutani N, Mogi A, Kuwano H.

World J Surg. 2017 Mar;41(3):771-779. doi: 10.1007/s00268-016-3802-9.

PMID:
27896403

Supplemental Content

Support Center